The Dexcom G6 CGM System.
Technology that lets us manage diabetes without fingersticks.*
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Meet the Dexcom G6.
A small, wearable continuously sends glucose readings to your smartphone† or Dexcom receiver - without fingersticks.*
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Easy to use‡
The Dexcom G6 is a small, discreet wearable that you apply yourself and lasts up to 10 days.
Goodbye fingersticks†
Glance at your smartphone.† See your glucose. Make diabetes treatment decisions. All without fingersticks.*
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Lowers A1C
Using a Dexcom CGM is proven to lower A1C and help you spend more time in range.1,2
“I struggled to lower my A1C until I got the Dexcom G6. Now it’s so much easier to stay on top of my glucose. My A1C is down 3 points.”§
Harrel C., Age 52
Dexcom Warrior
Individual results may vary.
Dexcom Warrior
Individual results may vary.
“I want all my Type 2 patients who depend on insulin to be on the Dexcom G6.”
Dr. Michael Heile, T1D
Endocrinologist
Paid spokesperson of Dexcom, Inc.
Endocrinologist
Paid spokesperson of Dexcom, Inc.
Get Started with Dexcom
Take the first step towards better health! Glucose health is a critical part of overall health, and Dexcom has the best sensing solution for you or your loved one regardless of your health goals. We'll make getting started easy from the comfort of your home.
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† For a list of compatible devices, visit http://www.dexcom.com/compatibility. Stable internet connection required.
‡ See user guide for set up instructions
§ Based upon a customer's experience; individual results may vary. Randomized controlled trial and real-world data indicate that Dexcom CGM use results in a mean A1C reduction of 0.8% (Beck RW et al. Ann Intern Med 2017;167(6):365-74) and 1.5% (Noar A, et al. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual) respectively, from baseline for patients with T2D.
1 Beck, RW. JAMA. 2017; 317(4); 371-378.
2 Welsh JB, et al. Diabetes Technol Ther 2019;21(3):128-32.
† For a list of compatible devices, visit http://www.dexcom.com/compatibility. Stable internet connection required.
‡ See user guide for set up instructions
§ Based upon a customer's experience; individual results may vary. Randomized controlled trial and real-world data indicate that Dexcom CGM use results in a mean A1C reduction of 0.8% (Beck RW et al. Ann Intern Med 2017;167(6):365-74) and 1.5% (Noar A, et al. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual) respectively, from baseline for patients with T2D.
1 Beck, RW. JAMA. 2017; 317(4); 371-378.
2 Welsh JB, et al. Diabetes Technol Ther 2019;21(3):128-32.
BRIEF SAFETY STATEMENT: Available by prescription only. Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www. dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. © 2020 Dexcom Inc. All rights reserved. This product is covered by U.S. patent.